

Cite this: *Chem. Sci.*, 2021, 12, 2841

All publication charges for this article have been paid for by the Royal Society of Chemistry

Diversified strategy for the synthesis of DNA-encoded oxindole libraries†

Xuan Wang,^{ab} Jiayang Liu,^a Ziqin Yan,^a Xiaohong Liu,^{cde} Sixiu Liu,^a Yanrui Suo,^a Weiwei Lu,^a Jinfeng Yue,^a Kaixian Chen,^{cde} Hualiang Jiang,^{cde} Yujun Zhao,^{id}*^a Mingyue Zheng,^{id}*^{de} Dongcheng Dai^{id}*^b and Xiaojie Lu^{id}*^a

DNA-encoded library technology (DEL) employs DNA as a barcode to track the sequence of chemical reactions and enables the design and synthesis of libraries with billions of small molecules through combinatorial expansion. This powerful technology platform has been successfully demonstrated for hit identification and target validation for many types of diseases. As a highly integrated technology platform, DEL is capable of accelerating the translation of synthetic chemistry by using on-DNA compatible reactions or off-DNA scaffold synthesis. Herein, we report the development of a series of novel on-DNA transformations based on oxindole scaffolds for the design and synthesis of diversity-oriented DNA-encoded libraries for screening. Specifically, we have developed 1,3-dipolar cyclizations, cyclopropanations, ring-opening of reactions of aziridines and Claisen–Schmidt condensations to construct diverse oxindole derivatives. The majority of these transformations enable a diversity-oriented synthesis of DNA-encoded oxindole libraries which have been used in the successful hit identification for three protein targets. We have demonstrated that a diversified strategy for DEL synthesis could accelerate the application of synthetic chemistry for drug discovery.

Received 8th December 2020
Accepted 31st December 2020

DOI: 10.1039/d0sc06696f

rsc.li/chemical-science

Introduction

The advances in molecular biology, in particular genomic sciences, has had a deep impact on the identification of potential disease-related protein targets in drug discovery.¹ Medicinal chemistry programs mostly rely on screening compound collections populated by a range of molecules derived from a set of known and robust chemical reactions. Based on the comprehensive analysis conducted by Dean G. Brown, high-throughput screening dominates early drug discovery, in conjunction with fragment-based screening and knowledge directed screens.² These lead generation strategies have successfully identified potential hit compounds, however the limited chemical space³ and high operation cost⁴ restricts the hit discovery for multiple

protein targets and limits the scope of application in small biotech startups and university laboratories due to prohibitive costs. It was through continued innovation by chemists that led to the introduction of DNA-encoded library technology pioneered in 1992 by Brenner and Lerner⁵ and has become a vital tool in the current investigational repertoire.

As an interdisciplinary technology, the integration of combinatorial chemistry, molecular biology, next generation DNA-sequencing and informatic analysis shaped the scene of the DNA-encoded library technology platform and brought it to a new level with larger compound collections, reduced operation costs and screening time. Barcoded small molecules translated from phage display⁶ with a small molecule warhead (phenotype) individually coupled to encoding DNA tags (genotype) serve to retrace the synthetic history. The encoded compound libraries were constructed using a combinatorial strategy followed by successive iterative steps of both chemical transformation and oligonucleotide ligation.⁷ DNA barcodes have facilitated affinity selection⁸ to interrogate vast numbers of compounds in a single pool, exceeding by several orders of magnitude the capacity of the traditional “one-compound per well” screening approach. The approach has dramatically decreased the cost and cycle times, and will become a general technology broadly applied to industry and academia alike.^{8,9}

Nevertheless, every new technology has strengths and weaknesses and DELT is no exception. The encoded compound collections are predominantly composed of limited scaffolds,

^aState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haik Road, Zhang Jiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China. E-mail: xjlu@simm.ac.cn

^bAmgen Asia R&D Center, Amgen Biopharmaceutical R&D (Shanghai) Co., Ltd., 4560 Jinke Road, Building No. 2, 13th Floor, Pudong, Shanghai 201210, P. R. China

^cShanghai Institute for Advanced Immunochemical Studies, School of Life Science and Technology, ShanghaiTech University, Pudong, Shanghai 201210, P. R. China

^dDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, P. R. China

^eUniversity of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, P. R. China

† Electronic supplementary information (ESI) available: Supplemental experimental procedures and supplemental data. See DOI: 10.1039/d0sc06696f



focused on peptides and aromatic rings.¹⁰ One reason for this limitation is that the scope of chemical reactions applicable in solution-phase DEL libraries are constrained to robust reactions that preserve the integrity of the oligonucleotides; few new synthetic methodologies can be applied to DEL library construction.¹¹ To preserve the integrity of the DNA barcodes, chemists have continued to expand the scope of mild chemical transformations and DNA-protecting strategies (solid-phase DEL,¹² reversible absorption of DNA onto resin,¹³ micellar catalyst-promoted reactions¹⁴), which provides new opportunities for DEL library synthesis.

In addition to the directed DNA protection strategy, diversified library construction could be enabled by the identification of mild chemical transformations. As illustrated in Fig. 1, a multitude of innovative chemistries were developed in academia to synthesize drug-like scaffolds, which could be introduced to the encoded library to expand chemical space through innovative designs. This route enables an enhancement of the crosstalk between synthetic and medicinal chemists in industry and academia and an opportunity to impact the future of drug discovery.¹⁵

In DELT library construction, an ideal scaffold provides mature synthetic methods, enabling synthesis both on-DNA or off-DNA and possessing multiple functional groups and appendage points for DNA-linking along with an abundance of readily available building blocks. Based on an extensive literature analysis, the oxindole core¹⁶ was selected to validate our initial proposal. Firstly, the C3 position of the oxindole could be converted into a number of diverse structures through well-established transformations; secondly, at least two functional groups are appended on these scaffolds; thirdly, oxindole-type compounds are prevalent in nature and have the potential to be transformed into drugs.

As illustrated in Fig. 2, four types of DELs were constructed from oxindoles to validate the concept: DEL-A, the




Fig. 2 Design and synthesis of diversified oxindole DNA-encoded libraries. (a) Isatin derivatives were commercially available or synthesized *via* Sandmeyer isatin synthesis. (b) On-DNA three-component cycloaddition reaction. (c) 3-Diazoisatin derivatives were transformed by 3-*N*-tosylhydrazone isatin derivatives under basic conditions. (d) PdCl₂-promoted on-DNA cyclopropanation reaction. (e) Spiroaziridine isatin derivatives were transformed by aza-Corey-Chaykovsky reaction. (f) On-DNA amidation reaction conditions. (g) On-DNA ring-opening reaction. (h) Oxindole derivatives were commercially available. (i) On-DNA Claisen-Schmidt condensation.

spiropyrrolizidine centered DEL was built on-DNA using a three-component cyclization reaction from available isatins **I**. DEL-B, the spirocyclopropyl centered DEL was synthesized by a palladium-promoted on-DNA cycloaddition reaction from diazoisatin derivatives **II**. DEL-C, spiroaziridine derivatives **III** were converted from **I** using an aza-Corey-Chaykovsky reaction, which then underwent a ring-opening reaction. DEL-D, unsaturated centered DEL was synthesized from oxindole **IV** by an on-DNA aldol reaction. These DELs arising from a simple oxindole core, spanned spiro, disubstituted and unsaturated structures, elegantly fit the diversity-oriented synthesis (DOS) strategy, which was recently demonstrated by Schreiber, *et al.*¹⁷

Results and discussion

Our efforts commenced with the investigation of on-DNA three-component reaction that can form highly functionalized spiro-pyrrolizidine/pyrrolizidine oxindoles.¹⁸ DNA barcodes could be




Fig. 1 The workflow of oxindole-scaffold DNA-encoded library.






Fig. 3 On-DNA three-component cyclization using three DNA-tagging points. (A) Three types of DNA-tagged spiropyrrolizidine centered modes. (B) Optimization of on-DNA three-component cyclization from acrylamide linked DNA oligonucleotides. Scope of substituted isatins, prolines and amino acids. (C) on-DNA reactions from DNA-linked 6. (a) Satin (200 equiv.), proline (300 equiv.), 80 °C, 3 h. (D) On-DNA cyclization reaction from DNA-linked 8. (b) Acryl ester (200 equiv.), proline (200 equiv.), rt, 3 h. (E) On-DNA cyclization reaction from DNA-linked 10. (c) Acryl ester (200 equiv.), proline (200 equiv.), rt, 3 h. Conversions determined by LCMS.

conjugated to the scaffold *via* three attachment sites: pyrrolizidine ring (1), nitrogen of oxindole (2) and aromatic ring (3), which could attenuate the steric hindrance caused by oligonucleotide tags and facilitate target–binder interactions by presenting multiple orientations (Fig. 3A).

As shown in Fig. 3B, DNA-linked acryl functionalized compound **1** was obtained in good conversion with 100 equiv. of isatin and 100 equiv. of proline *via* a three-component cyclization reaction at 30 °C. We observed that higher reaction temperatures were required for converting the starting material **1** to the desired products with some of the substituted isatins (Fig. 3B, **4c** and **4d**). The lack of reactivity in **4e** at 80 °C was presumably a consequence of the steric hindrance of the chloride substitution. Elevated temperatures also caused the formation of side products and DNA decomposition. A representative set of experimental results showing the interplay between temperature and isatin derivatives is found in the ESI S2.† 50 °C was chosen as the preferred temperature to balance product formation and minimize side product formation.

Further diversity was explored with cyclic/acyclic α -amino acids (Fig. 3B). Cyclic amino acids such as thiazolidine-4-carboxylic acid and 4-hydroxypyrrolidine-2-carboxylic acid

provided moderate conversions under the optimized reaction conditions. Only benzyl-functionalized acyclic amino acid variants provided the desired products at 80 °C, likely due to the decreased stability of the intermediate. DNA-appended acrylamide **6** *via* on-DNA Heck coupling reaction developed previously were also tested in this annulation reaction (Fig. 3C) and moderate conversions were obtained, proving the possibility of two on-DNA methodologies in sequence. Next, we turned to isatin-functionalized DNA headpieces covalently linked through amide bond formation (Fig. 3D and E). We observed formation of the desired product along with 50% of byproduct, which had a molecular weight of desired product plus 18 Da (ESI S5†). Several amide bond forming reaction conditions were tested with no improvement in the product ratio. Fortunately, these byproducts didn't impact the subsequent on-DNA spiroannulation reaction under the optimized reaction conditions. In addition, we also carried out the proof-of-concept synthesis to apply this new on-DNA annulation reaction *via* Heck cross-coupling reaction,¹⁹ Suzuki cross-coupling,²⁰ nitro reduction, reductive amination and amide bond formation. These transformations could be found in the ESI S6.†




Fig. 4 On-DNA cyclopropanation reaction.




Fig. 5 On-DNA ring-opening reactions by nucleophiles.



Spirocyclopropyl oxindoles are useful building blocks with a broad spectrum of biological and pharmaceutical applications such as HIV-1 NNRT1 inhibitors and arginine vasopressin inhibitors.²¹ Various approaches to access spirocyclopropyl fragments have been established between diazo compounds and electron-deficient olefins using a variety of metal catalysts. In particular, InCl_3 has been demonstrated to promote reaction with 3-diazoindole and electro-deficient olefins in the presence

of water.²¹ This was the preferred starting point to develop the corresponding DNA-compatible cycloaddition reactions. A range of promoters including Cu, Ag, Pd, Pt, Au, Ru, Ga, Mg, Fe and Zr were tested and PdCl_2 provided 67% of the desired on-DNA spirocyclopropyl oxindole **13a**. Unreacted DNA-conjugated acryl represented the mass balance at 100 °C, and low DNA recovery was found upon LC-MS analysis (ESI S7,† Fig. 4). Unfortunately, lower reaction temperatures also significantly decreased the conversions. Meanwhile, a proof-of-concept library synthesis using ester functionalized diazoisatin **12b** as a bifunctional chemical linker was performed, providing the desired product **13b**. After hydrolysis, the resulting carboxylic acid **13c** enabled further diversity *via* acylation but with low conversion (**13d**, 10% conversion). Although this on-DNA set of reaction conditions was not robust enough for constructing spirocyclopropyl centered DNA-encoded libraries due to the low DNA recovery and suboptimal conversions to the desired products, it opens the door for more future exploration of this type of on-DNA transformation.

Highly strained spiroaziridine oxindoles and 3,3'-disubstituted oxindoles are attracting attention for their interesting bioactivities.²² We proposed to synthesize the spiroaziridine oxindole scaffolds first followed by DNA barcoding conjugation. DEL-C was constructed *via* DNA compatible ring-opening reactions to introduce aliphatic amines and phenol building blocks into the library. As illustrated in Fig. 5, the starting point for this exploration was the synthesis of carboxylic acid functionalized




Fig. 6 On-DNA Claisen–Schmidt condensation reaction.




Fig. 7 (A) The structures of DNA-encoded libraries. DNA-encoded library A, which was divided into five sub-libraries: DEL-A1, a di-synthon library; DEL-A2, a tri-synthon library contained a Heck coupling reaction; DEL-A3, a tri-synthon library contained a Suzuki coupling reaction; DEL-A4, a tri-synthon library contained an amidation reaction, reductive amination reaction and urea formation; DEL-A5, a tri-synthon library contained an amidation reaction, these reaction schemes are listed in S6 of ESI;† DNA-encoded library C based on DNA-compatible ring-opening methodology; DNA-encoded library D based on DNA compatible Claisen condensation methodology. (B) Physicochemical property distribution of DELs, including AlogP, HBA, HBD, MW, RB, TPSA and PCA. For PCA, PC means principal component, and it's a linear combination of variables (e.g. MW, AlogP, etc.). Each PC value accounts for the percentage of the total variance around the PCs. When PC1 & PC2 accounts for the majority of the variation (>70%), we could use a 2D graph to represent the chemical space.



spiroaziridine oxindoles. From the methodologies established over past decades, we selected an aza-Corey–Chaykovsky reaction²³ to access the aziridine unit *via* the addition of sulfur ylides to isatin derived *N-tert*-butanesulfinyl ketimines. Following oxidation and ester hydrolysis, the desired scaffold 14 was covalently linked to DNA barcoding *via* DMTMM promoted amide formation. We next turned to investigate the aminolysis and hydrolysis of the aziridine motif through a DNA-compatible ring-opening reaction. Both aliphatic amines and phenols provided moderate to excellent conversions. Weakly nucleophilic aromatic amines showed a lack of reactivity. Meanwhile, we also observed that DNA-conjugated 3,3'-dihydroxyoxindoles were formed as byproducts at elevated temperatures under basic conditions, possibly due to the residual base in the final step. Therefore, a spin filter procedure was required to remove the remaining basic reagents and to maintain neutral conditions. The corresponding DEL construction and validation are described in the next section.

2-Indolinone is a well-known scaffold and present in drugs for cancer treatment.^{16e,24} 'Two tagging points' were employed to construct 3-alkenyl oxindole DNA-encoded libraries *via* a Claisen–Schmidt condensation reaction of substituted

indoline-2-ones with various aldehydes in the presence of TEA (Fig. 6). Both aliphatic aldehydes and aromatic aldehydes delivered modest to excellent conversions. However, ketones gave negligible product formation even under forcing basic conditions, possibly due to relatively low nucleophilicity. Depending on the targets to be screened, such libraries may provide potential starting points for covalent drugs. The corresponding DEL construction and validation are described in the next section.

Encoded libraries construction

DNA-encoded libraries **A**, **C** and **D** were constructed by the newly developed DNA-compatible reactions with readily accessible building blocks such as amino acids, amines, borates and aldehydes. The size of the combined libraries was approximately 1.05 million (Fig. 7A). To determine the physicochemical properties of the compounds that compose the three libraries, 6000 compounds were randomly selected to summarize the physicochemical properties as shown in Fig. 7B. The full library molecule (tri-synthon) have a slightly higher molecule weight (*ca.* 650 Da on average) than Lipinski rule-of-5 compliant




Fig. 8 Selection outcomes of DELs-A3–5. (A) Selection data analysis of DEL-A3 for BRD4-BD1. (B) Selection data analysis of DEL-A4 for BRD4-BD1. (C) Selection data analysis of DEL-A5 for BRD4-BD1. (D) Selection data analysis of DEL-A3 for Aurora. (E) Selection data analysis of DEL-A4 for P300. (F) Validation of three compounds **21**, **22**, and **23** by off-DNA resynthesis and biochemical assay data. (G) Validation of two compounds **24** and **25** by off-DNA resynthesis and IC₅₀ assay data.



compounds, while the other properties meet the range of the typical hit compound profiles. Comparing the chemical space of DELs with 10 752 compounds from DrugBank, we applied the Principle Component Analysis (PCA) for both pool and found the overlap between them was more than 90%.

Not surprisingly, the properties of the di-synthon with the oxindole core were more attractive for hit-to-lead optimization. To evaluate whether the divergent isatin based DEL also worked for the screening of biological targets, we performed affinity screenings for three protein targets BRD4-BD1 (Fig. 8A–C), Aurora A (Fig. 8D) and p300 (Fig. 8E). DEL-A library pool was screened against BRD4-BD1 protein using the known inhibitor JQ1²⁵ as a positive control. After the affinity screening, the samples were subjected to NGS and the generated data was translated into the corresponding copy number for the data analysis. In order to fully analyze the data among five different isatin libraries (DEL A1–A5), we used the enrichment for the normalization of different DELs²⁶ (see the ESI† for the enrichment calculation). Fig. 8A–E illustrated the three-dimensional view of the corresponding selection outcomes for each individual library. From the data analysis, we found that DEL-A3–5 had obvious features for the BRD4-BD1, and the competition experiment with JQ1 further confirmed that the features are competitive binders likely within the similar binding pocket with JQ1 (ESI S8†). As illustrated in the three cubes (Fig. 8A–C), nascent SAR has been identified for DEL A3–5. From the detailed analysis, we have synthesized the truncated compounds **21–23** for activity confirmation with BRD2, BRD3 and BRD4. All synthesized compounds have moderate Ki values which demonstrated our rationale for the design and synthesis of the diversified oxindole libraries.

For Aurora A, we found the libraries had features with moderate enrichment (<100) in “target” and low in the “no target” control. However, obvious SAR has been identified for the cycle 3 BBs (Fig. 8D). **3_184** and **3_135** have similar structures and the latter was selected for synthesis off-DNA (**24**). **24** showed weak activity against Aurora A, demonstrating that moderate enrichment also could correlate with binding affinity. For the p300, a potential feature was found in DEL-A4 with good enrichment and the cycle 3 BB **3_147** was selected (Fig. 8E). Truncated structure **25** was synthesized off-DNA and validated in a biochemical assay. **25** showed weak activity against the target, but demonstrated the potential for multi-target selection with our designed DELs.

Conclusion

In summary, based on the oxindole scaffolds, we have developed a series of on-DNA synthetic transformations including 1,3-dipolar cyclization, cyclopropanation, ring-opening of aziridines and Claisen–Schmidt condensations to construct diverse oxindole derivatives. Among these reactions, the cyclopropanation and ring-opening reaction of aziridines are the first reported examples of on-DNA reactions, which opens the door for future exploration and applications. The majority of these transformations enable the diversity-oriented synthesis of DNA-encoded oxindole libraries which have been demonstrated with

the design and synthesis of spiropyrrolizidine-oxindole DEL A libraries. Three protein targets have been screened and active hit compounds were identified and confirmed with moderate to good activities. Expanding the scope of synthetic transformations compatible for DEL library synthesis, particularly based on the oxindole scaffolds, more active hits could be identified as starting points for medicinal chemistry programs. In addition, oxindole libraries based on the novel on-DNA reactions are currently under construction and additional results from DEL selections will be reported in the due course.

Experimental procedures

Full details of synthesis and LC-MS/MS analysis are provided in the ESI.†

Author contributions

Jiaxiang Liu, Ziqin Yan, and Xiaohong Liu contributed equally to this article.

Conflicts of interest

The authors declare no competing interests.

Acknowledgements

We gratefully acknowledge financial support from the National Natural Science Foundation of China (81773634 to M. Z., 21877117 and 91953203 to X. L., 21907103 to X. W., 81673295 to Y. Z.), National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program”, China (Number: 2018ZX09711002 to H. J., No. 2018ZX09711002-005 to X. L.), and “Personalized Medicines—Molecular Signature-based Drug Discovery and Development”, Strategic Priority Research Program of the Chinese Academy of Sciences (XDA12050201 to M. Z.; XDA12040330 and XDA12050405 to X. L.), Shanghai Commission of Science and Technology (18431907100 to X. L.). We also thank Dr Ryan Wurz of Amgen for critical reading.

References

- (a) M. Schenone, V. Dancik, B. K. Wagner and P. A. Clemons, *Nat. Chem. Biol.*, 2013, **9**, 232–240; (b) C. Finan, A. Gaulton, F. A. Kruger, R. T. Lumbers, T. Shah, J. Engmann, L. Galver, R. Kelley, A. Karlsson, R. Santos, J. P. Overington, A. D. Hingorani and J. P. Casas, *Sci. Transl. Med.*, 2017, **9**, eaag1166; (c) M. Luo, J. Jiao and R. Wang, *BMC Bioinf.*, 2019, **20**, 198.
- D. G. Brown and J. Bostrom, *J. Med. Chem.*, 2018, **61**, 9442–9468.
- (a) J. L. Reymond and M. Awale, *ACS Chem. Neurosci.*, 2012, **3**, 649–657; (b) M. González-Medina, J. J. Naveja, N. Sánchez-Cruz and J. L. Medina-Franco, *RSC Adv.*, 2017, **7**, 54153–54163.
- S. Morgan, P. Grootendorst, J. Lexchin, C. Cunningham and D. Greyson, *Health Policy*, 2011, **100**, 4–17.



- 5 S. Brenner and R. A. Lerner, *Proc. Natl. Acad. Sci. U. S. A.*, 1992, **89**, 5381–5383.
- 6 G. P. Smith and V. A. Petrenko, *Chem. Rev.*, 1997, **97**, 391–410.
- 7 M. A. Clark, R. A. Acharya, C. C. Arico-Muendel, S. L. Belyanskaya, D. R. Benjamin, N. R. Carlson, P. A. Centrella, C. H. Chiu, S. P. Creaser, J. W. Cuzzo, C. P. Davie, Y. Ding, G. J. Franklin, K. D. Franzen, M. L. Gefter, S. P. Hale, N. J. Hansen, D. I. Israel, J. Jiang, M. J. Kavarana, M. S. Kelley, C. S. Kollmann, F. Li, K. Lind, S. Mataruse, P. F. Medeiros, J. A. Messer, P. Myers, H. O'Keefe, M. C. Oliff, C. E. Rise, A. L. Satz, S. R. Skinner, J. L. Svendsen, L. Tang, K. van Vloten, R. W. Wagner, G. Yao, B. Zhao and B. A. Morgan, *Nat. Chem. Biol.*, 2009, **5**, 647–654.
- 8 D. Neri and R. A. Lerner, *Annu. Rev. Biochem.*, 2018, **87**, 479–502.
- 9 (a) F. Buller, L. Mannocci, J. Scheuermann and D. Neri, *Bioconjugate Chem.*, 2010, **21**, 1571–1580; (b) M. A. Clark, *Curr. Opin. Chem. Biol.*, 2010, **14**, 396–403; (c) R. E. Kleiner, C. E. Dumelin and D. R. Liu, *Chem. Soc. Rev.*, 2011, **40**, 5707–5717; (d) R. M. Franzini, D. Neri and J. Scheuermann, *Acc. Chem. Res.*, 2014, **47**, 1247–1255; (e) H. Salamon, M. Klika Skopic, K. Jung, O. Bugain and A. Brunschweiler, *ACS Chem. Biol.*, 2016, **11**, 296–307; (f) S. L. Belyanskaya, Y. Ding, J. F. Callahan, A. L. Lazaar and D. I. Israel, *ChemBioChem*, 2017, **18**, 837–842; (g) R. A. Goodnow Jr, C. E. Dumelin and A. D. Keefe, *Nat. Rev. Drug Discovery*, 2017, **16**, 131–147; (h) N. Favalli, G. Bassi, J. Scheuermann and D. Neri, *FEBS Lett.*, 2018, **592**, 2168–2180; (i) Y. Zhou, C. Li, J. Peng, L. Xie, L. Meng, Q. Li, J. Zhang, X. D. Li, X. Li, X. Huang and X. Li, *J. Am. Chem. Soc.*, 2018, **140**, 15859–15867; (j) P. Dickson and T. Kodadek, *Org. Biomol. Chem.*, 2019, **17**, 4676–4688; (k) J. Ottl, L. Leder, J. V. Schaefer and C. E. Dumelin, *Molecules*, 2019, **24**, 1629.
- 10 R. M. Franzini and C. Randolph, *J. Med. Chem.*, 2016, **59**, 6629–6644.
- 11 (a) Z. J. Gartner, M. W. Kanan and D. R. Liu, *Angew. Chem., Int. Ed.*, 2002, **41**, 1796–1800; (b) A. L. Satz, J. Cai, Y. Chen, R. Goodnow, F. Gruber, A. Kowalczyk, A. Petersen, G. Naderi-Oboodi, L. Orzechowski and Q. Strebler, *Bioconjugate Chem.*, 2015, **26**, 1623–1632; (c) M. L. Malone and B. M. Paegel, *ACS Comb. Sci.*, 2016, **18**, 182–187; (d) K. Götte, S. Chines and A. Brunschweiler, *Tetrahedron Lett.*, 2020, 151889.
- 12 M. Potowski, F. Losch, E. Wunnemann, J. K. Dahmen, S. Chines and A. Brunschweiler, *Chem. Sci.*, 2019, **10**, 10481–10492.
- 13 (a) D. T. Flood, S. Asai, X. Zhang, J. Wang, L. Yoon, Z. C. Adams, B. C. Dillingham, B. B. Sanchez, J. C. Vantourout, M. E. Flanagan, D. W. Piotrowski, P. Richardson, S. A. Green, R. A. Shenvi, J. S. Chen, P. S. Baran and P. E. Dawson, *J. Am. Chem. Soc.*, 2019, **141**, 9998–10006; (b) Y. Ruff, R. Martinez, X. Pelle, P. Nimsgern, P. Fille, M. Ratnikov and F. Berst, *ACS Comb. Sci.*, 2020, **22**, 120–128.
- 14 (a) M. K. Skopic, K. Gotte, C. Gramse, M. Dieter, S. Pospich, S. Raunser, R. Weberskirch and A. Brunschweiler, *J. Am. Chem. Soc.*, 2019, **141**, 10546–10555; (b) J. H. Hunter, L. Prendergast, L. F. Valente, A. Madin, G. Pairedeau and M. J. Waring, *Bioconjugate Chem.*, 2020, **31**, 149–155.
- 15 D. P. Rotella, *ACS Chem. Neurosci.*, 2016, **7**, 1315–1316.
- 16 (a) N. R. Ball-Jones, J. J. Badillo and A. K. Franz, *Org. Biomol. Chem.*, 2012, **10**, 5165–5181; (b) L. Hong and R. Wang, *Adv. Synth. Catal.*, 2013, **355**, 1023–1052; (c) M. A. Borad, M. N. Bhoi, N. P. Prajapati and H. D. Patel, *Synth. Commun.*, 2014, **44**, 1043–1057; (d) M. Xia and R.-Z. Ma, *J. Heterocycl. Chem.*, 2014, **51**, 539–554; (e) A. Leoni, A. Locatelli, R. Morigi and M. Rambaldi, *Expert Opin. Ther. Pat.*, 2016, **26**, 149–173; (f) G. Muller, T. Berkenbosch, J. C. Benningshof, D. Stumpfe and J. Bajorath, *Chemistry*, 2017, **23**, 703–710; (g) G. J. Mei and F. Shi, *Chem. Commun.*, 2018, **54**, 6607–6621.
- 17 C. J. Gerry, M. J. Wawer, P. A. Clemons and S. L. Schreiber, *J. Am. Chem. Soc.*, 2019, **141**, 10225–10235.
- 18 (a) S. Rehn, J. Bergman and B. Stensland, *Eur. J. Org. Chem.*, 2004, **2004**, 413–418; (b) T. L. Pavlovskaya, F. G. Yaremenko, V. V. Lipson, S. V. Shishkina, O. V. Shishkin, V. I. Musatov and A. S. Karpenko, *Beilstein J. Org. Chem.*, 2014, **10**, 117–126.
- 19 X. Wang, H. Sun, J. Liu, W. Zhong, M. Zhang, H. Zhou, D. Dai and X. Lu, *Org. Lett.*, 2019, **21**, 719–723.
- 20 Y. Ding and M. A. Clark, *ACS Comb. Sci.*, 2015, **17**, 1–4.
- 21 S. Muthusamy and R. Ramkumar, *Synlett*, 2015, **26**, 2156–2160.
- 22 (a) F. M. Ismail, D. O. Levitsky and V. M. Dembitsky, *Eur. J. Med. Chem.*, 2009, **44**, 3373–3387; (b) J. Kaur, S. S. Chimni, S. Mahajan and A. Kumar, *RSC Adv.*, 2015, **5**, 52481–52496; (c) G. Zhu, S. Liu, S. Wu, L. Peng, J. Qu and B. Wang, *J. Org. Chem.*, 2017, **82**, 4317–4327; (d) S. Hajra, S. Singha Roy, A. Biswas and S. A. Saleh, *J. Org. Chem.*, 2018, **83**, 3633–3644.
- 23 (a) E. J. Corey and M. Chaykovsky, *J. Am. Chem. Soc.*, 1965, **87**, 1353–1364; (b) S. Hajra, S. M. Aziz, B. Jana, P. Mahish and D. Das, *Org. Lett.*, 2016, **18**, 532–535.
- 24 A. Andreani, *Eur. J. Med. Chem.*, 1990, **25**, 187–190.
- 25 P. Filippakopoulos, J. Qi, S. Picaud, Y. Shen, W. B. Smith, O. Fedorov, E. M. Morse, T. Keates, T. T. Hickman, I. Felletar, M. Philpott, S. Munro, M. R. McKeown, Y. Wang, A. L. Christie, N. West, M. J. Cameron, B. Schwartz, T. D. Heightman, N. La Thangue, C. A. French, O. Wiest, A. L. Kung, S. Knapp and J. E. Bradner, *Nature*, 2010, **468**, 1067–1073.
- 26 R. M. Franzini, T. Ekblad, N. Zhong, M. Wichert, W. Decurtins, A. Nauer, M. Zimmermann, F. Samain, J. Scheuermann, P. J. Brown, J. Hall, S. Graslund, H. Schuler and D. Neri, *Angew. Chem., Int. Ed.*, 2015, **54**, 3927–3931.

